Androxal enclomiphene: Interim Phase III data

Interim 6-month data from 150 men <60 years of age with a BMI of >25 in the single-blind, placebo-controlled Phase III ZA-303 trial showed no evidence that Androxal reduced BMD as assessed by dual x-r...